Replies to post #189142 on Biotech Values

[GrthzGd]

Who would benefit from the trial of a drug seen as likely to fail in P3, and why would a pharma pay for such a trial?

[masterlongevity]

the FDA does not require a shred of efficacy to move to phase 3. you only have to give them confidence that the drug is safe enough to test in a larger group of patients.